BIOA insider transaction filings
BioAge Labs, Inc. — 38 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-01. Screen BIOA transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-01 | 4 | Barton Shane — Principal Accounting Officer | Option exercise (M): 9,301 @ $10.85 · Option exercise (M): 7,261 @ $8.39 · Option exercise (M): 8,958 @ $4.30 · Option exercise (M): 14,198 @ $4.38 · Sale (S): 42,350 @ $25.21 · Option exercise (M): 4,290 @ $10.85 · +12 more | EDGAR |
| 2026-06-12 | 4 | Pande Vijay Satyanand — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Hemrajani Rekha — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Davidson Michael H. — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | ENRIGHT PATRICK G — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | HEALY JAMES — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | GARNIER JEAN PIERRE — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2026-04-24 | 4 | GOLDSTEIN DOV A MD — Chief Financial Officer | Option exercise (M): 3,542 @ $4.38 · Option exercise (M): 3,542 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | RUBIN PAUL D — Chief Medical Officer | Option exercise (M): 5,437 @ $4.11 · Option exercise (M): 3,383 @ $6.57 · Sale (S): 8,820 @ $17.81 · Option exercise (M): 5,437 (derivative) @ $0 · Option exercise (M): 3,383 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | RUBIN PAUL D — Chief Medical Officer | Option exercise (M): 5,433 @ $4.11 · Option exercise (M): 2,000 @ $6.57 · Sale (S): 7,433 @ $20.30 · Option exercise (M): 5,433 (derivative) @ $0 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | GOLDSTEIN DOV A MD — Chief Financial Officer | Option exercise (M): 3,542 @ $4.38 · Option exercise (M): 3,542 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Morgen Eric — Chief Operating Officer, Director | Grant/award (A): 110,000 (derivative) @ $0 · Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Fortney Kristen — Chief Executive Officer, Director | Grant/award (A): 330,000 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Barton Shane — Principal Accounting Officer | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | RUBIN PAUL D — Chief Medical Officer | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | GOLDSTEIN DOV A MD — Chief Financial Officer | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | RUBIN PAUL D — Chief Medical Officer | Option exercise (M): 5,433 @ $4.11 · Option exercise (M): 2,000 @ $6.57 · Sale (S): 7,433 @ $18.75 · Option exercise (M): 5,433 (derivative) @ $0 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | GOLDSTEIN DOV A MD — Chief Financial Officer | Option exercise (M): 3,541 @ $4.38 · Option exercise (M): 3,541 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | GOLDSTEIN DOV A MD — Chief Financial Officer | Option exercise (M): 3,542 @ $4.38 · Option exercise (M): 3,542 (derivative) @ $0 | EDGAR |
| 2026-01-15 | 4 | Fortney Kristen — Chief Executive Officer, Director | Sale (S): 233,107 @ $18.12 | EDGAR |
| 2026-01-15 | 4 | GOLDSTEIN DOV A MD — Chief Financial Officer | Option exercise (M): 27,000 @ $8.39 · Sale (S): 8,974 @ $18.43 · Sale (S): 4,440 @ $19.45 · Sale (S): 11,663 @ $20.54 · Sale (S): 1,923 @ $21.08 · Option exercise (M): 27,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | RUBIN PAUL D — Chief Medical Officer | Option exercise (M): 5,433 @ $4.11 · Option exercise (M): 2,000 @ $6.57 · Sale (S): 7,433 @ $12.85 · Option exercise (M): 5,433 (derivative) @ $0 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2025-12-11 | 4 | RUBIN PAUL D — Chief Medical Officer | Option exercise (M): 18,000 @ $6.57 · Sale (S): 18,000 @ $12 · Option exercise (M): 18,000 (derivative) @ $0 | EDGAR |
| 2025-12-05 | 4 | RUBIN PAUL D — Chief Medical Officer | Option exercise (M): 68,897 @ $4.11 · Sale (S): 68,897 @ $10.19 · Option exercise (M): 68,897 (derivative) @ $0 | EDGAR |
| 2025-08-11 | 4 | Pande Vijay Satyanand — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Hemrajani Rekha — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Davidson Michael H. — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | ENRIGHT PATRICK G — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | HEALY JAMES — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | GARNIER JEAN PIERRE — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-03-10 | 4 | Barton Shane — Principal Accounting Officer | Purchase (P): 2,632 @ $18 | EDGAR |
| 2025-03-10 | 4/A | Hemrajani Rekha — Director | Purchase (P): 3,000 @ $18 | EDGAR |
| 2025-02-25 | 4/A | Morgen Eric — Chief Operating Officer, Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Morgen Eric — Chief Operating Officer, Director | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Fortney Kristen — Chief Executive Officer, Director | Grant/award (A): 530,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Barton Shane — Principal Accounting Officer | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | RUBIN PAUL D — Chief Medical Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | GOLDSTEIN DOV A MD — Chief Financial Officer | Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — BioAge Labs, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-08 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-24 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-20 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-04 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BIOA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →